CUMBERLAND PHARMACEUTICALS INC - Common stock (CPIX)
CUSIP: 230770109
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common stock
- Shares outstanding
- 15,075,924
- Total 13F shares
- 3,682,268
- Share change
- -597,746
- Total reported value
- $12,334,180
- Put/Call ratio
- 0%
- Price per share
- $3.35
- Number of holders
- 30
- Value change
- -$2,453,600
- Number of buys
- 14
- Number of sells
- 18
Quarterly Holders Quick Answers
What is CUSIP 230770109?
CUSIP 230770109 identifies CPIX - CUMBERLAND PHARMACEUTICALS INC - Common stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 230770109:
Top shareholders of CPIX - CUMBERLAND PHARMACEUTICALS INC - Common stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Ikarian Capital, LLC |
13D/G
13F
|
Company |
4.9%
|
730,932
|
$3,545,020 | $0 | 31 Mar 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
5.4%
|
809,897
|
$3,425,864 | — | 31 Mar 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
3.3%
|
503,363
|
$2,129,225 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
2.8%
|
416,569
|
$1,762,087 | — | 31 Mar 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
1.7%
|
252,189
|
$1,066,760 | — | 31 Mar 2025 | |
| J. Goldman & Co LP |
13F
|
Company |
1.6%
|
241,481
|
$1,021,465 | — | 31 Mar 2025 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
1.5%
|
223,798
|
$946,666 | — | 31 Mar 2025 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.2%
|
184,155
|
$778,976 | — | 31 Mar 2025 | |
| BERKSHIRE ASSET MANAGEMENT LLC/PA |
13F
|
Company |
1%
|
153,810
|
$692,145 | — | 31 Mar 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
0.99%
|
150,000
|
$634,500 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.66%
|
99,091
|
$419,222 | — | 31 Mar 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.48%
|
72,513
|
$306,730 | — | 31 Mar 2025 | |
| Informed Momentum Co LLC |
13F
|
Company |
0.48%
|
71,776
|
$303,612 | — | 31 Mar 2025 | |
| Walleye Capital LLC |
13F
|
Company |
0.47%
|
70,419
|
$297,872 | — | 31 Mar 2025 | |
| Martin E. Cearnal |
3/4/5
|
Sr VP/Chief Commercial Officer, Director |
—
class O/S missing
|
163,473
|
$277,904 | — | 17 Mar 2022 | |
| Leo Pavliv |
3/4/5
|
SVP and Chief Development Off. |
—
class O/S missing
|
129,618
|
$220,351 | — | 31 May 2022 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
0.33%
|
49,137
|
$207,000 | — | 31 Mar 2025 | |
| Joey A. Jacobs |
3/4/5
|
Director |
—
class O/S missing
|
98,415
|
$167,306 | — | 14 Jan 2023 | |
| STATE STREET CORP |
13F
|
Company |
0.22%
|
33,700
|
$142,551 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0.22%
|
32,658
|
$138,143 | — | 31 Mar 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.19%
|
28,939
|
$122,412 | — | 31 Mar 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.17%
|
25,814
|
$109,193 | — | 31 Mar 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.15%
|
22,755
|
$96,254 | — | 31 Mar 2025 | |
| Cresset Asset Management, LLC |
13F
|
Company |
0.13%
|
19,975
|
$84,494 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.13%
|
19,603
|
$82,921 | — | 31 Mar 2025 | |
| SIMPLEX TRADING, LLC |
13F
|
Company |
0.13%
|
19,100
|
$80,000 | — | 31 Mar 2025 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.12%
|
17,900
|
$75,717 | — | 31 Mar 2025 | |
| &PARTNERS |
13F
|
Company |
0.07%
|
11,000
|
$48,510 | — | 31 Mar 2025 | |
| Jonathan Griggs |
3/4/5
|
Director |
—
class O/S missing
|
14,803
|
$25,165 | — | 17 Mar 2021 | |
| UBS Group AG |
13F
|
Company |
0.04%
|
5,337
|
$22,576 | — | 31 Mar 2025 | |
| Michael Bonner |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
11,720
|
$19,924 | — | 17 Mar 2021 | |
| MORGAN STANLEY |
13F
|
Company |
0.02%
|
2,660
|
$11,252 | — | 31 Mar 2025 | |
| Centiva Capital, LP |
13F
|
Company |
0.01%
|
1,600
|
$6,768 | — | 31 Mar 2025 | |
| Capital Advisors, Ltd. LLC |
13F
|
Company |
0%
|
437
|
$2,000 | — | 31 Mar 2025 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
250
|
$1,058 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
68
|
$288 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
19
|
$80 | — | 31 Mar 2025 | |
| HUNTINGTON NATIONAL BANK |
13F
|
Company |
0%
|
1
|
$4 | — | 31 Mar 2025 |
Institutional Holders of CUMBERLAND PHARMACEUTICALS INC - Common stock (CPIX) as of Q2 2025
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
An asterisk sign (*) next to the price indicates that the price is likely invalid.